[Expression and its clinical significance of tissue factor pathway inhibitor and antithrombin-III in patients with hepatic inflammatory diseases].
OBJECTIVE
To investigate the change and clinical significance of tissue factor pathway inhibitor (TFPI) and antithrombin-III (AT-III) in the plasma of patients with hepatic inflammatory disease (HID).


METHODS
The plasma levels and activation of TFPI and AT-III in patients with HID (Group I, n = 82) were compared to that in healthy people (Group II as control, n = 30).


RESULTS
The plasma level of TFPI:Ag in Group I was higher (P < 0.05) and its activation was also increased dramatically (P < 0.01), the level of AT-III: A was lower in patients with chronic hepatitis B (P < 0.05) and no difference was found in other indices between the two groups.


CONCLUSIONS
The elevation of TFPI:Ag and TFPI:A in hepatic inflammatory diseases is an indication of inflammation, and hepatic tissue injury in broad, the lower level of AT-III liver secretions.
Dong
L
L
People's Hospital of Baoan District, Shenzhen.
Peng
Y
Y
Wang
R
R
D000328:Adult; D000368:Aged; D000990:Antithrombin III / Q000032:analysis*; D005260:Female; D006505:Hepatitis / Q000097:blood*; D006801:Humans; D008074:Lipoproteins / Q000097:blood*; D008297:Male; D008875:Middle Aged
D008074:Lipoproteins; C051928:lipoprotein-associated coagulation inhibitor; D000990:Antithrombin III